Collectively, these findings suggest that miR-1 enhances cisplatin responsiveness in NSCLC by suppressing ATG3-driven autophagy, highlighting the miR-1/ATG3 axis as a promising therapeutic target for overcoming chemoresistance. This evidence concerns the gene ATG3 and non-small cell lung carcinoma.